Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration

Emir Kobic; Christian M Gill; A Brian Mochon; Nelson P Nicolasora; David P Nicolau

doi:10.1093/ofid/ofab252

Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration

Open Forum Infect Dis. 2021 May 25;8(7):ofab252. doi: 10.1093/ofid/ofab252. eCollection 2021 Jul.

Authors

Emir Kobic¹, Christian M Gill², A Brian Mochon^{3

4}, Nelson P Nicolasora⁵, David P Nicolau^{2

6}

Affiliations

¹ Department of Pharmacy, Banner University Medical Center, Phoenix, Arizona, USA.
² Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
³ Department of Pathology, University of Arizona College of Medicine, Phoenix, Arizona, USA.
⁴ Labratory Sciences Arizona/Sonora Quest Laboratories, Phoenix, Arizona, USA.
⁵ Division of Infectious Diseases, Banner University Medical Center, Phoenix, Arizona, USA.
⁶ Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA.

Abstract

Antimicrobial dosing in patients receiving continuous renal replacement therapy is a continued clinical challenge. We describe a case of a patient receiving cefiderocol 2 g intravenously every 8 hours as a 3-hour infusion for a multidrug-resistant Pseudomonas aeruginosa pneumonia and bacteremia while undergoing continuous venovenous hemodiafiltration. The clinical course and cefiderocol pharmacokinetics are described.

Keywords: CRRT; CVVHDF; antimicrobial dosing; cefiderocol; continuous renal replacement therapy; pharmacodynamics; pharmacokinetics.

Publication types

Case Reports